Phase B-STYPE
II I-STYPE
Trial I-STYPE
of O
De O
- O
Intensified O
Chemoradiotherapy O
for O
Human O
Papillomavirus O
- O
Associated O
Oropharyngeal O
Squamous O
Cell O
Carcinoma O
Phase B-STYPE
II I-STYPE
Trial I-STYPE
of O
De O
- O
Intensified O
Chemoradiotherapy O
for O
Human O
Papillomavirus O
- O
Associated O
Oropharyngeal O
Squamous O
Cell O
Carcinoma O
MDBhishamjitSChera B-AUTH

Novartis O
, O
Zimmer O
Becton O
Dickinson O
Baxter O
, O
Merck O
, O
Pfizer O
, O
Stryker O
, O
Procter O
& O
Gamble O
, O
Walgreens O
Novartis O
, O
Zimmer O
Cardinal O
Health O
, O
Express O
Scripts O
Becton O
Dickinson O

Novartis O
, O
Zimmer O
Becton O
Dickinson O
Baxter O
, O
Merck O
, O
Pfizer O
, O
Stryker O
, O
Procter O
& O
Gamble O
, O
Walgreens O
Novartis O
, O
Zimmer O
Phase B-STYPE
II I-STYPE
Trial I-STYPE
of O
De O
- O
Intensified O
Chemoradiotherapy O
for O
Human O
Papillomavirus O
- O
Associated O
Oropharyngeal O
Squamous O
Cell O
Carcinoma O
10.1200 O
/ O
JCO.19 O
Accepted O
on O
July O
19 O
, O
2019 O
and O
published O
at O
jco.org O
on O
August O
14 O
, O
2019 O
: O

This O
phase B-STYPE
II I-STYPE
study I-STYPE
was O
registered O
with O
the O
National O
Cancer O
Institute O
and O
was O
approved O
by O
the O
institutional O
review O
boards O
at O
the O
participating O
centers O
. O
All O
patients O
provided O
written O
informed O
consent O
. O
Enrolling O
institutions O
included O
the O
University O
of O
North O
Carolina O
Hospitals O
( O
Chapel O
Hill O
, O
NC O
) O
, O
University O
of O
Florida O
Hospitals O
( O
Gainesville O
, O
FL O
) O
, O
Rex O
Hospital O
( O
Raleigh O
, O
NC O
) O
, O
High O
Point O
Regional O
Cancer O
Center O
( O
High O
Point O
, O
NC O
) O
, O
and O
Pardee O
Hospital O
( O
Hendersonville O
, O
NC O
) O
. O

Eligible O
patients O
had O
untreated O
, O
pathologically O
confirmed O
p16 O
positive O
squamous O
cell O
carcinoma O
of O
the O
oropharynx O
or O
from O
an O
unknown O
head O
and O
neck O
primary O
site O
; O
were O
18 O
years O
of O
age O
or O
older O
; O
had O
American O
Joint O
Committee O
on O
Cancer O
( O
AJCC O
) O
7th O
edition O
T0-T3 O
, O
N0-N2c O
, O
M0 O
( O
AJCC O
8th O
edition O
T0-T3 O
, O
N0-N2 O
, O
M0 O
) O
; O
reported O
10 O
pack O
- O
years O
or O
less O
of O
smoking O
history O
or O
30 O
pack O
- O
years O
or O
less O
and O
abstinence O
for O
the O
past O
5 O
years O
; O
had O
an O
Eastern O
Cooperative O
Oncology O
Group O
performance O
status O
of O
0 O
to O
1 O
; O
had O
adequate O
hematologic O
, O
renal O
, O
and O
liver O
function O
; O
and O
had O
no O
history O
of O
prior O
head O
and O
neck O
cancers O
. O
Human O
papilloma O
virus O
and O
p16 O
were O
analyzed O
per O
institutional O
standards O
by O
florescence O
in O
- O
situ O
hybridization O
or O
immune O
histochemistry O
; O
p16 O
positivity O
was O
defined O
as O
more O
than O
70 O
% O
of O
carcinoma O
cells O
showing O
nuclear O
reactivity O
. O

All O
patients O
had O
standard O
- O
of O
- O
care O
pretreatment O
evaluations O
and O
staging O
procedures O
, O
including O
( O
1 O
) O
a O
complete O
history O
and O
physical O
examination O
( O
including O
fiber O
optic O
nasolaryngopharyngoscopy O
) O
, O
( O
2 O
) O
panendoscopy O
with O
directed O
biopsies O
and O
tonsillectomies O
if O
the O
primary O
was O
unknown O
, O

( O
3 O
) O
at O
least O
one O
diagnostic O
contrasted O
neck O
and O
chest O
CT O
, O
and O
( O
4 O
) O
standard O
hematologic O
, O
liver O
, O
and O
renal O
blood O
studies O
. O
No O
patients O
had O
a O
definitive O
surgery O
( O
ie O
, O
transoral O
resection O
) O
. O

All O
patients O
were O
treated O
with O
IMRT B-DESC
. O
The O
total O
dose O
to O
the O
high O
- O
risk O
regions O
was O
60 B-DOSAGE
Gy I-DOSAGE
at I-DOSAGE
2 I-DOSAGE
Gy I-DOSAGE
per I-DOSAGE
fraction I-DOSAGE
, I-DOSAGE
30 I-DOSAGE
fractions I-DOSAGE
, I-DOSAGE
5 I-DOSAGE
days I-DOSAGE
a I-DOSAGE
week I-DOSAGE
, I-DOSAGE
for I-DOSAGE
6 I-DOSAGE
weeks I-DOSAGE
. O
Fifty B-DOSAGE
- I-DOSAGE
four I-DOSAGE
gray I-DOSAGE
was I-DOSAGE
delivered I-DOSAGE
to I-DOSAGE
anatomic I-DOSAGE
regions I-DOSAGE
at I-DOSAGE
risk I-DOSAGE
of I-DOSAGE
subclinical I-DOSAGE
disease I-DOSAGE
as O
indicated O
( O
eg O
, O
ipsilateral O
levels O
1B O
to O
5 O
, O
contralateral O
cervical O
levels O
2 O
to O
4 O
, O
and O
retropharyngeal O
lymph O
node O
basins O
) O
. O
Unilateral O
radiotherapy O
( O
RT O
) O
was O
permitted O
in O
patients O
with O
well O
- O
lateralized O
tonsil O
primaries O
. O

Cisplatin B-DESC
30 B-DOSAGE
mg I-DOSAGE
/ I-DOSAGE
m I-DOSAGE
2 I-DOSAGE
once I-DOSAGE
per I-DOSAGE
week I-DOSAGE
was O
the O
mandated O
firstchoice O
chemotherapy O
; O
however O
, O
alternative O
regimens O
once O
per O
week O
were O
permissible O
. O
Typical O
reasons O
for O
a O
patient O
not O
being O
able O
to O
receive O
cisplatin O
included O
renal O
insufficiency O
and O
history O
of O
hearing O
loss O
and/or O
tinnitus O
. O
The O
preferred O
second- O
, O
third- O
, O
and O
fourth O
- O
choice O
chemotherapies O
were O
( O
1 O
) O
cetuximab B-DESC
250 O
mg O
/ O
m O
2 O
, O
( O
2 O
) O
carboplatin B-DESC
area O
under O
the O
curve O
1.5 O
and O
paclitaxel B-DESC
45 O
mg O
/ O
m O
2 O
, O
and O
( O
3 O
) O
carboplatin B-DESC
area O
under O
the O
curve O
3 O
. O
Chemotherapy B-DOSAGE
was I-DOSAGE
given I-DOSAGE
intravenously I-DOSAGE
once I-DOSAGE
per I-DOSAGE
week I-DOSAGE
, I-DOSAGE
preferably I-DOSAGE
on I-DOSAGE
Mondays I-DOSAGE
. I-DOSAGE
Six I-DOSAGE
weekly I-DOSAGE
doses I-DOSAGE
were I-DOSAGE
given I-DOSAGE
concurrently I-DOSAGE
with I-DOSAGE
radiation I-DOSAGE
( I-DOSAGE
ie I-DOSAGE
once I-DOSAGE
per I-DOSAGE
week I-DOSAGE
for I-DOSAGE
6 I-DOSAGE
weeks I-DOSAGE
) I-DOSAGE
. O
Dose O
modifications O
were O
allowed O
as O
needed O
per O
the O
treating O
medical O
oncologist O
's O
discretion O
. O
If O
a O
patient O
could O
not O
tolerate O
cisplatin O
for O
more O
than O
1 O
week O
, O
he O
or O
she O
was O
switched O
to O
an O
alternative O
regimen O
. O
Chemotherapy O
was O
not O
given O
to O
patients O
with O
T0 O
- O
2 O
N0 O
- O
1 O
disease O
( O
AJCC O
7th O
edition O
) O
. O

Clinical O
response O
to O
CRT O
was O
evaluated O
10 O
to O
16 O
weeks O
after O
CRT O
with O
a O
PET O
/ O
CT O
and O
clinical O
examinations O
by O
the O
treating O
radiation O
oncologist O
and O
head O
and O
neck O
surgeon O
. O
Decisions O
for O
surgical O
intervention O
( O
ie O
, O
biopsy O
, O
neck O
dissection O
) O
were O
based O
on O
the O
PET O
/ O
CT O
and O
clinical O
evaluations O
demonstrating O
suspicion O
of O
residual O
tumor O
. O

Patients O
were O
observed O
clinically O
every O
2 O
to O
3 O
months O
for O
2 O
years O
, O
then O
every O
6 O
months O
for O
3 O
additional O
years O
. O
Chest O
imaging O
was O
performed O
every O
6 O
months O
for O
2 O
years O
and O
then O
yearly O
. O

Clinician O
assessments O
of O
toxicity O
( O
National O
Cancer O
Institute O
's O
Common O
Terminology O
Criteria O
for O
Adverse O
Events O
[ O
CTCAE O
] O
version O
4.03 O
) O
and O
patient O
self O
- O
reported O
symptoms O
( O
patient O
- O
reported O
outcomes O
version O
of O
the O
CTCAE O
[ O
PRO O
- O
CTCAE O
] O
) O
were O
collected O
before O
treatment O
, O
weekly O
during O
treatment O
, O
and O
during O
subsequent O
follow O
- O
up O
visits O
. O
16,17 O
Thirty O
head O
and O
neck O
- O
specific O
items O
were O
selected O
from O
the O
PRO O
- O
CTCAE O
. O
18 O
Patients O
also O
completed O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Questionnaire O
( O
EORTC O
QLQ O
) O
C30 O
, O
EORTC O
QLQ O
H&N35 O
, O
and O
Eating O
Assessment O
Tool O
10 O
questionnaires O
before O
treatment O
, O
weekly O
during O
treatment O
, O
and O
during O
subsequent O
follow O
- O
up O
visits O
. O
[ O
19][20][21 O
] O
Modified O
barium O
swallow O
studies O
were O
performed O
before O
treatment O
, O
6 O
to O
8 O
weeks O
after O
treatment O
, O
and O
6 O
months O
after O
treatment O
. O
The O
Rosenbek O
Penetration O
Aspiration O
Scale O
was O
used O
to O
quantify O
dysphagia O
. O
22 O